Two Nonsynonymous Single Nucleotide Polymorphisms of Human Carbonyl Reductase 1 Demonstrate Reduced in Vitro Metabolism of Daunorubicin and Doxorubicin

Drug Metabolism and Disposition

Volumn 37, Issue 5, 2009, Pages 1107-1114

  Bains, Onkar S ^a   Karkling, Morgan J ^a   Grigliatti, Thomas A ^a   Reid, Ronald E ^a   Riggs, K Wayne ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARBONYL REDUCTASE; CARBONYL REDUCTASE 1; DAUNORUBICIN; DAUNORUBICINOL; DOXORUBICIN; DOXORUBICINOL; DRUG METABOLITE; HISTIDINE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER PATIENT; CBR1 GENE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG RESEARCH; ENZYME ACTIVITY; ENZYME SPECIFICITY; FLUORESCENCE ANALYSIS; GENE; GENE MUTATION; GENETIC VARIABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; P131S GENE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; V88I GENE;

ALCOHOL OXIDOREDUCTASES; ALLELES; ANTIBIOTICS, ANTINEOPLASTIC; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLONING, MOLECULAR; DAUNORUBICIN; DOXORUBICIN; HUMANS; KINETICS; MODELS, MOLECULAR; POLYMORPHISM, SINGLE NUCLEOTIDE; RECOMBINANT PROTEINS; VITAMIN K 3;

EID: 66449103252     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.024711     Document Type: Article

References (34)

1. Bains OS, Takahashi RH, Pfeifer TA, Grigliatti TA, Reid RE, and Riggs KW (2008) Two allelic variants of aldo-ketoreductase 1A1 exhibit reduced in vitro metabolism of daunorubicin. Drug Metab Dispos 36:904-910.
2. Barry E, Alvarez JA, Scully RE, Miller TL, and Lipshultz SE (2007) Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharma- cother 8:1039-1058.
3. Bateman R, Rauh D, and Shokat KM (2007) Glutathione traps formaldehyde by formation of a bicycle[4.4.1]undecane adduct. Org Biomol Chem 5:3363-3367.
4. Cortes-Funes H and Coronado C (2007) Role of anthracyclines in the era of targeted therapy. Cardiovasc Toxicol 7:56-60.
5. Danesi R, Fogli S, Gennari A, Conte P, and Del Tacca M (2002) Pharmacokinetic pharmaco- dynamic relationships of the anthracycline anticancer drugs. Clin Pharmacokinet 41:431-444.
6. Deng S and Wojnowski L (2007) Genotyping the risk of anthracycline- induced cardiotoxicity. Cardiovasc Toxicol 7:129-134.
7. Fassas A and Anagnostopoulos A (2005) The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia. Leuk Lymphoma 46:795-802.
8. Forrest GL and Gonzalez B (2000) Carbonyl reductase. Chem Biol Interact 129:21-40.
9. Gianni L, Salvatorelli E, and Minotti G (2007) Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes. Cardiovasc Toxicol 7:67-71.
10. Gonzalez-Covarrubias V, Ghosh D, Lakhman SS, Pendyala L, and Blanco JG (2007) A functional genetic polymorphism on human carbonyl reductase 1 (CBR1 V88I) impacts on catalytic activity and NADPH binding affinity. Drug Metab Dispos 35:973-980.
11. Hasinoff BB, Schnabl KL, Marusak RA, Patel D, and Huebner E (2003) Dexrazoxane (ICRF- 187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria. Cardiovasc Toxicol 3:89-99.
12. Hoffmann F and Maser E (2007) Carbonyl reductases and pluripotent hydroxysteroid dehydrogenases of the short-chain dehydrogenase/reductase superfamily. Drug Metab Rev 39:87-144.
13. Hunault-Berger M, Milpied N, Bernard M, Jouet JP, Delain M, Desablens B, Sadoun A, Guilhot F, Casassus P, and Ifrah N (2001) Daunorubicin continuous infusion induces more toxicity than bolus infusion in acute lymphoblastic leukemia induction regimen: a randomized study. Leukemia 15:898-902.
14. Kim DS, Kim HR, Woo ER, Hong ST, Chae HJ, and Chae SW (2005) Inhibitory effects of rosmarinic acid on Adriamycin-induced apoptosis in H9c2 cardiac muscle cells by inhibiting reactive oxygen species and the activations of c-Jun N-terminal kinase and extracellular signal-regulated kinase. Biochem Pharmacol 70:1066-1078.
15. Licata S, Saponiero A, Mordente A, and Minotti G (2000) Doxorubicin metabolism and toxicity in human myocardium: role of cytoplasmic deglycosidation and carbonyl reduction. Chem Res Toxicol 13:414-420.
16. Lipp HP and Bokemeyer C (1999) Anthracyclines and other intercalating agents, in Anticancer Drug Toxicity: Prevention, Management and Clinical Pharmacokinetics (Lipp HP ed) pp 81-113, Marcel Dekker, New York.
17. Matsunaga T, Shintani S, and Hara A (2006) Multiplicity of mammalian reductases for xeno- biotic carbonyl compounds. Drug Metab Pharmacokinet 21:1-18.
18. Menna P, Recalcati S, Cairo G, and Minotti G (2007) An introduction to the metabolic determinants of anthracycline cardiotoxicity. Cardiovasc Toxicol 7:80-85.
19. Minotti G, Cairo G, and Monti E (1999) Role of iron in anthracycline cardiotoxicity: new tunes for an old song? FASEB J 13:199-212.
20. Minotti G, Menna P, Salvatorelli E, Cairo G, and Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185-229.
21. Mordente A, Meucci E, Martorana GE, Giardina B, and Minotti G (2001) Human heart cytosolic reductases and anthracycline cardiotoxicity. IUBMB Life 52:83-88.
22. Ohara K, Shin M, Larsson LI, and Fujiwara K (2007) Improved immunocytochemical detection of daunomycin. Histochem Cell Biol 127:603-608.
23. Oppermann UC (2007) Carbonyl reductases: the complex relationships of mammalian carbonyl- and quinone-reducing enzymes and their role in physiology. Annu Rev Pharmacol Toxicol 47:293-322.
24. Plebuch M, Soldan M, Hungerer C, Koch L, and Maser E (2007) Increased resistance of tumor cells to daunorubicin after transfection of cDNAs coding for anthracycline inactivating enzymes. Cancer Lett 255:49-56.
25. Scully RE and Lipshultz SE (2007) Anthracycline cardiotoxicity in long-term survivors of childhood cancer. Cardiovasc Toxicol 7:122-128.
26. SingalPK, LiT, KumarD, DanelisenI, andIliskovic N(2000)Adriamycin- inducedheartfailure: mechanism and modulation. Mol Cell Biochem 207:77-86.
27. Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, Jones SE, Wadler S, Desai A, Vogel C, et al. (1997) Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15:1318-1332.
28. Takemura G and Fujiwara H (2007) Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 49:330-352.
29. Wallace KB (2003) Doxorubicin-induced cardiac mitochondrionopathy. Pharmacol Toxicol 93:105-115.
30. Wexler LH, Andrich MP, Venzon D, Berg SL, Weaver-McClure L, Chen CC, Dilsizian V, Avila N, Jarosinski P, Balis FM, et al. (1996) Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 14:362-372.
31. Wirth H and Wermuth B (1992) Immunohistochemical localization of carbonyl reductase in human tissues. J Histochem Cytochem 40:1857-1863.
32. Wojtacki J, Lewicka-Nowak E, and Lesniewski-Kmak K (2000) Anthracycline-induced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and prevention-review of the literature. Med Sci Monit 6:411-420.
33. Wold LE, Aberle NS 2nd, and Ren J (2005) Doxorubicin induces cardiomyocyte dysfunction via a p38 MAP kinase-dependent oxidative stress mechanism. Cancer Detect Prev 29:294-299.
34. Wu X and Hasinoff BB (2005) The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species. Anticancer Drugs 16:93-99.